11 registrations that name alpha-lipoic acid as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 11 registrations
Status
Phase
2US sites across 2 states
1
2 to 4
5 to 19
20 or more
All 11 registrations
RecruitingNCT07501663
Optimizing Integrative Oncology Approaches to Address Chemotherapy-induced Peripheral Neuropathy in Gastrointestinal (GI) Cancer Patients: A SMART Pilot Study
No phase
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
About 60 people
Started Jan 20, 2026
In plain words A study of alpha-lipoic acid in people 18 and older, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. It plans to enroll about 60 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Peripheral Neuropathy.
Individuals must meet all the following inclusion criteria in order to be eligible to participate in the study:
Age 18 years or older,
Self-reported moderate (≥ 2/4) numbness and tingling on the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Numbness and Tingling Severity Item in the previous week,
At least three months since the last receipt of neurotoxic chemotherapy,
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Tai Chi/Qi Gong; α- Lipoic acid; Acupuncture
Registered summary
The objective of the proposed pilot is to test the feasibility, acceptability, and preliminary efficacy of a 16-week sequential, multiple assessment randomized trial (SMART), which includes virtual Tai Chi/Qi Gong or α- Lipoic acid (ALA) supplements as an initial treatment, and acupuncture as the additional treatment, that examines a stepped-care intervention to address CIPN.
Where, as registered
1 US site in 1 state.
RecruitingNCT07877948
Comparative Study of Combination Treatment of Bionerv E+ Versus Vitamin B Complex in Treatment of Diabetic Polyneuropathy in Type 2 Diabetic Patients and Its Effect on Wound Healing
No phase
BREGO Life Sciences
About 100 people
Started Jul 22, 2025
In plain words A study of alpha-lipoic acid in people 18 and older, run by BREGO Life Sciences. It plans to enroll about 100 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Diabetic Foot Ulcer (DFU); Diabetic Symmetrical Polyneuropathy.
Aged 18 years and above
Diagnosed with Type 2 Diabetes Mellitus
HbA1C of <8%
Symptoms of DSPN attributed by diabetes mellitus using Toronto Clinical Neuropathy Scoring (TCNS)
12 more inclusion criteria and the exclusion criteria are on the listing.
Diabetic symmetrical polyneuropathy (DSPN) is a common complication of diabetes that affects the nerves, especially in the legs and feet. It can cause pain, numbness, tingling, weakness, and loss of sensation. These problems can affect daily activities and quality of life. Loss of sensation can also increase the risk of foot wounds and problems with wound healing. This study is comparing two treatments in people with type 2 diabetes and DSPN. The full summary is on the listing.
Where, as registered
No US site; Malaysia (1).
RecruitingNCT07312123
A Study to See Whether Taking a Mix of Vitamins Can Help Adults Recover Better After Surgery for Carpal Tunnel Syndrome
No phase
Hospital Universiti Sains Malaysia
About 84 people
Started Dec 8, 2025
In plain words A study of alpha-lipoic acid in people 18 and older, run by Hospital Universiti Sains Malaysia. It plans to enroll about 84 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Carpal Tunnel Syndrome.
Age more than 18 years old
Subjects with symptoms and physical examination of CTS
Patients with CTS going for CT release
The exclusion criteria are on the listing.
What it tests, as registered
Alpha-Lipoic Acid, Vitamin E, and Vitamin B Complex; Combination Vitamin B1,B6,B12
Registered summary
Carpal Tunnel Syndrome (CTS) is a common condition that causes numbness, tingling, pain, and weakness in the hand due to compression of the median nerve at the wrist. It can affect daily activities, work performance, and quality of life. While surgery is effective in severe cases, many patients with mild to moderate CTS are initially treated with non-surgical options such as splinting and medications. However, the effectiveness of oral supplements for CTS remains uncertain. The full summary is on the listing.
Where, as registered
No US site; Malaysia (1).
RecruitingNCT07685431
Alpha-Lipoic Acid Supplementation and IVF Outcomes in Women of Advanced Maternal Age
No phase
Kaohsiung Veterans General Hospital.
About 60 people
Started Jun 11, 2026
In plain words A study of alpha-lipoic acid in female participants 35 to 45, run by Kaohsiung Veterans General Hospital.. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 35 to 45. Conditions: Female Infertility Due to Diminished Ovarian Reserve.
Age 35-45 years
BMI 18-35 kg/m²
Planning to undergo IVF treatment using own oocytes
The exclusion criteria are on the listing.
What it tests, as registered
Alpha-Lipoic Acid (ALA)
Registered summary
Female fertility declines with advancing age, largely because of deteriorating oocyte quality driven by mitochondrial dysfunction and oxidative stress within the ovarian microenvironment. Alpha-lipoic acid (ALA) is a potent antioxidant that crosses cell and mitochondrial membranes, regenerates other antioxidants (vitamin C, vitamin E, glutathione, coenzyme Q10), and supports mitochondrial respiratory chain activity and ATP production. This prospective study will enroll 60 infertile women aged 35-45 years undergoing in vitro fertilization (IVF) treatment. The full summary is on the listing.
Where, as registered
No US site; Taiwan (1).
RecruitingNCT07564479
Alpha-Lipoic Acid in Mitigating Cisplatin-Induced Nephrotoxicity
Phase 2
Minia University
About 50 people
Started Mar 10, 2026
In plain words A Phase 2 study of alpha-lipoic acid in people 18 and older, run by Minia University. It plans to enroll about 50 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Cisplatin Nephrotoxicity; Nephrotoxicity.
Age ≥ 18 years. Histologically confirmed solid malignancy. Planned treatment with cisplatin starting from a dose of 60 mg/m2 per cycle (21-28 days each or fractionated).
The exclusion criteria are on the listing.
What it tests, as registered
Alpha-Lipoic Acid (ALA)
Registered summary
To assess the nephroprotective efficacy of Alpha-Lipoic Acid in preventing cisplatin-induced nephrotoxicity in oncology patients by monitoring renal function changes
Where, as registered
No US site; Egypt (1).
RecruitingNCT07256119
Evaluation of the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients
No phase
Ain Shams University
About 40 people
Started Aug 6, 2024
In plain words A study of alpha-lipoic acid in female participants 18 to 75, run by Ain Shams University. It plans to enroll about 40 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 75. Conditions: Prevention.
Women aged ≥18 years.
Histologically confirmed invasive, early-stage breast carcinoma scheduled for adjuvant radiotherapy.
Receiving total radiation dose of 40 Gy for 15 sessions.
The exclusion criteria are on the listing.
What it tests, as registered
Alpha Lipoic Acid
Registered summary
the purpose of this study is to evaluate the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients
Where, as registered
No US site; Egypt (1).
Not yet recruitingNCT05713799
Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity
Phase 2
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
About 60 people
Starts Oct 22, 2026 (estimated)
In plain words A Phase 2 study of alpha-lipoic acid in people 18 to 65, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). It plans to enroll about 60 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65; healthy volunteers accepted. Conditions: Insulin Resistance; Obesity.
Adults 18 to 65 years of age
BMI greater than or equal to 30 kg/m\^2 and less than or equal to 45 kg/m\^2
The exclusion criteria are on the listing.
What it tests, as registered
Alpha-lipoic acid; Mirabegron; Placebo
Registered summary
Background: Obesity and related illnesses cause at least 2.8 million deaths each year worldwide. Few treatments exist for obesity that are safe and widely available. A study drug (mirabegron \[MG\]) combined with a supplement (alpha-lipoic acid \[ALA\]) may help. Objective: To learn how MG and ALA can help the body process food. Eligibility: People aged 18 to 65 years with a body mass index between 30 and 45 kg/m2. Design: Participants will be screened. They will have a physical exam. They will have blood and urine tests and a test of their heart function. They will speak with a dietician. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07725484
Efficacy of Lipoic Acid on Chronic Ischemic Heart Failure Patients
Phase 3
Shanghai Zhongshan Hospital
About 1,526 people
Starts Nov 1, 2026 (estimated)
In plain words A Phase 3 study of alpha-lipoic acid in people 18 to 75, run by Shanghai Zhongshan Hospital. It plans to enroll about 1,526 people at 21 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Heart Failure Due to Coronary Artery Disease.
Aged 18 years or older and younger than 75 years at the time of enrollment.
A history of chronic heart failure for more than 3 months, or clinical symptoms of heart failure lasting more than 3 months, diagnosed according to the 2023 European Society of Cardiology guidelines for the diagnosis and treatment of…
Left ventricular ejection fraction (LVEF) of 40% or less, as assessed by echocardiography.
A history of acute myocardial infarction more than 3 months prior to enrollment, diagnosed according to the Fourth Universal Definition of Myocardial Infarction.
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Alpha-Lipoic Acid (ALA); placebo
Registered summary
Chronic heart failure is a clinical condition caused by structural heart disease and is characterized by reduced pumping function, fluid retention, and abnormal activation of neurohormonal systems. It represents the advanced stage of many cardiovascular diseases and remains a major global health challenge. Despite progress in medical and interventional therapies, patients with chronic heart failure continue to experience high rates of death, hospitalization, and long-term disability. The full summary is on the listing.
Where, as registered
No US site; China (21).
Not yet recruitingNCT07360379
Comparing N-Acetylcysteine (NAC) Versus Alpha-Lipoic Acid (ALA) as Adjuncts for Postoperative Pain Management After Laparoscopic Appendectomy
No phase
Ain Shams University
About 180 people
Starts Dec 28, 2025 (estimated)
In plain words A study of alpha-lipoic acid in people 18 to 65, run by Ain Shams University. It plans to enroll about 180 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Laparoscopic Appendectomy; Pain Management; Anti Oxidative Stress.
Age 18-65 years, either sex
ASA physical status I-III
Undergoing laparoscopic appendectomy
Able to provide informed consent and take oral medications postoperatively
The exclusion criteria are on the listing.
What it tests, as registered
N Acetyl Cysteine; Alpha-Lipoic Acid (ALA); Placebo
Registered summary
Postoperative pain remains a major concern following laparoscopic appendectomy, despite advances in minimally invasive surgery and multimodal analgesia. Inadequate pain control delays recovery, prolongs hospital stay, and increases opioid consumption with associated adverse effects. Therefore, identifying safe adjunct therapies that enhance analgesia and reduce opioid requirements is an important clinical goal. Oxidative stress and inflammation play a critical role in the development and maintenance of postoperative pain. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07785544
Efficacy and Safety of Low-Dose Duloxetine Plus Alpha-Lipoic Acid Versus Standard-Dose Duloxetine in Painful Diabetic Peripheral Neuropathy
No phase
Bangladesh Medical University
About 170 people
Starts Aug 25, 2026 (estimated)
In plain words A study of alpha-lipoic acid in people 18 and older, run by Bangladesh Medical University. It plans to enroll about 170 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Painful Diabetic Peripheral Neuropathy.
Age ≥18 years.
Diagnosed case of diabetes mellitus.
Diabetic peripheral neuropathy diagnosed clinically according to the Toronto Clinical Neuropathy Score (TCNS) criteria with a TCNS score ≥6, with painful neuropathy confirmed using the Leeds Assessment of Neuropathic Symptoms and Signs…
Duration of neuropathic symptoms ≥3 months.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Duloxetine; Alpha-Lipoic Acid
Registered summary
This study will evaluate the efficacy and safety of low-dose duloxetine combined with alpha-lipoic acid compared with standard-dose duloxetine in adults with painful diabetic peripheral neuropathy. In this assessor-blinded, randomized, parallel-arm, non-inferiority trial, participants will be assigned in a 1:1 ratio to receive either duloxetine 30 mg once daily plus alpha-lipoic acid 600 mg once daily or duloxetine 60 mg once daily. The primary outcome will be the change in pain intensity measured by the Numerical Rating Scale from baseline to Week 9. The full summary is on the listing.
Where, as registered
No US site; Bangladesh (1).
Not yet recruitingNCT07399743
Effects of Lower Body Positive Pressure Therapy Versus Alpha Lipoic Acid and Omega-3 Fatty Acids on Knee Osteoarthritis
Phase 3
Badr University
About 160 people
Starts Feb 15, 2026 (estimated)
In plain words A Phase 3 study of alpha-lipoic acid in female participants 20 to 45, run by Badr University. It plans to enroll about 160 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists female participants 20 to 45. Conditions: Knee Osteoarthritis.
Female participants aged between 20-45 years.
Their BMI ranged between 20-25 kg/m².
All had radiographic confirmation of mild to moderate knee osteoarthritis.
Medical history recorded with no major prior injuries or surgeries affecting outcomes.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Alpha-Lipoic Acid (ALA)+PT; Omega-3 cap+ PT; Lower body positive pressure therapy (LBPP)+PT; Standard physical therapy (PT)
Registered summary
Here is a \*\*concise, clear summary (\~250 words / well under 5000 characters)\*\* while preserving the key scientific points: \--- Knee osteoarthritis (KOA) is highly prevalent among overweight women, affecting more than 30% of those with BMI ≥25 kg/m². Excess body weight increases knee joint loading by 4-6 times per additional kilogram, accelerating cartilage degeneration, subchondral bone changes, and synovial inflammation. The full summary is on the listing.
Where, as registered
No sites listed yet.
ClinicalTrials.gov lists 27 open registrations for this search, including ones where alpha-lipoic acid is not a study arm or that are past the 11 we keep. Search them on ClinicalTrials.gov (opens in new tab).